Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Subscribe
Login
Password
Password
Remember me
Forgot password?
Close login form
Market Reports
Digitalisation in specialty chemicals and pharmaceuticals
Paige Marie Morse, Industry Director, AspenTech talks to Dr Kevin Robinson about accelerating innovation and optimising the value chain with digital technologies
Supporting precision with precision
As biologics steadily grow in pipeline development and commercialisation, they inherently require precise and meticulous support to ensure effective delivery to the patient
The economic advantages of continuous flow chemistry
Batch production has been the traditional workhorse of the pharmaceutical manufacturing sector. However, economic advantages are taking continuous flow out of the realm of a niche technology for high energy, hazardous reactions to become an essential part of the small molecule manufacturing toolkit
The modularisation of chemical API synthesis
The modularisation of chemical synthesis pathways in pharmaceutical production can improve overall plant efficiency and reduce planning time. Glatt Ingenieurtechnik has optimised the active pharmaceutical ingredient (API) synthesis process and developed bespoke plant designs for several international customers
Rare diseases: understanding the patient journey
In the shadow of Rare Disease Day on 28 February 2019, Dr Kevin Robinson met with Zizi Imatorbhebhe, Senior Director of Strategic Development and Head of PAREXEL’s Rare Disease Center of Excellence (RDCE), to discuss the future of rare disease research
A new paradigm in vaccines and cancer treatments
Specialist pharmaceutical company N4 Pharma is developing Nuvec, a unique non-viral adjuvant delivery system for vaccines and cancer treatments. This silica nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines. Dr Kevin Robinson recently caught up with Nigel Theobald, CEO of N4 Pharma, to find out more
Fuelling pharma’s innovation engines
Wishing to assess the current state of Alcami’s target market, Dr Kevin Robinson recently sat down with President and CEO, Dr Stephan Kutzer, to discuss its health, innovation and future aspirations
Broad stripes, bright stars and a thriving pharmaceutical industry: part I
According to one of Stephen Sondheim’s most well-known lyrics, “I like to be in America! OK by me in America!” But, given the geography, politics, population, regulation and funding that are unique to the United States, Dr Kevin Robinson looked west to the Land of the Free to find out how the pharmaceutical industry is faring amongst all the milk and honey
The hidden risk of contamination
Pharmaceutical companies may be unwittingly putting production processes at risk of contamination by fitting pumps with mechanical seals that fail to comply with industry regulations, says John Smiddy, European Sales and Technical Support Director for AESSEAL
A revolutionary method of liquid flow measurement
Pharmaceutical supplier opts for innovative hygienic flowmeter
Next-generation safety testing
In vitro genetic testing offers an ethical alternative to animal testing, which is also cheaper, faster and more reliable
Developments and the future of pharmaceutical packaging
With the global primary packaging market in the pharmaceutical sector expected to experience remarkable growth during the next few years, Dr Kevin Robinson asked a number of industry experts to comment on the hurdles, drivers and emerging trends that are influencing how drugs are formulated, packaged and delivered
Is the production of biologic drugs ready for an overhaul?
Is the industry ready for a new manufacturing model? Mark Emalfarb, President and CEO of Dyadic International, thinks so and explains why to Dr Kevin Robinson
Leaders of transformation
Haig Armaghanian, founder and CEO of Haig Barrett, explores how synthetic biology pioneers are revolutionising therapeutic development
Continuous manufacturing: the facts and the future
Many companies talk about continuous manufacturing (CM), but few speak with the experience of actually implementing a continuous process line. Dr Kevin Robinson spoke to GEA’s Richard Steiner to find out why
Looking back on 2018 and making predictions for 2019
As the global pharmaceutical industry transitions from the knowns of 2018 into the unknowns of 2019, Dr Kevin Robinson caught up with some of the key players in the market to assess the year that was and the 12 months to come in terms of upcoming trends and developments
Serialisation is not enough
A global technology leader in supply chain security, Systech’s revolutionary solution provides authentic, safe and connected products throughout the pharmaceutical supply chain. Dr Kevin Robinson recently caught up with CEO Ara Ohanian to find out more
Preparing PIs for post EU-FMD success
Ian Haynes of Excellis Europe explains how the company’s unique approach to enabling collaboration between parallel importers is helping to simplify the transition to serialisation post EU-FMD
Eliminating the time thieves
Comprehensive scientific process engineering (CSPE) cuts delivery times and accelerates the commissioning of pharmaceutical systems. Dr Kevin Robinson spoke to Optima Pharma’s Gerhard Breu to find out more
Formulating for success with ODTs
An ageing global population, consumer demand for greater convenience and the need to improve patient compliance are driving the development of new platforms for orally disintegrating dosage forms
Choosing effective granulation strategies for effervescent formulations
Effervescent tablets and instant drinks are attractive dosage forms for healthcare companies looking to meet the needs of modern patients and consumers
FMD: clarification for wholesalers, distributors and logistics partners
Christian Taylor, Serialisation Business Consultant at Zetes, clears up some of the key pain points when it comes to the practical application of the Falsified Medicines Directive (FMD)
Serialisation and data connectivity: Part II
The new wrinkle in your supply chain, <a href='https://www.manufacturingchemist.com/news/article_page/Serialisation_and_data_connectivity_Part_I/147850'>click here to read part I</a>
Serialisation and data connectivity: Part I
The new wrinkle in your supply chain
Previous
1
…
4
5
6
7
8
(current)
9
10
Next
Trending Articles
NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer
The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
You need to be a subscriber to read this article.
Click here
to find out more.
How CRDMOs are shaping the next generation of antibody-drug conjugates
To explore how CRDMOs are leading innovation in ADC development, Dr Kevin Robinson spoke with Srivats Rajagopal, Senior Director, Cell and Protein Sciences, Biology Solutions at Aragen Life Sciences, about key technological advancements and evolving partnership models that are redefining what it means to outsource in this space
Influence of material and capsule filling process on DPI aerosolisation performance
The effect of capsule filling parameters on emitted dose and fine particle fraction by a DPI was investigated using a benchtop capsule filling device. Compression was the parameter that affected weight and emitted fraction the most, whereas the type of coarse lactose seems to influence the fine particle fraction
The economic advantages of continuous flow chemistry
Batch production has been the traditional workhorse of the pharmaceutical manufacturing sector. However, economic advantages are taking continuous flow out of the realm of a niche technology for high energy, hazardous reactions to become an essential part of the small molecule manufacturing toolkit
Recombinant versus synthetic peptide synthesis: the perks and drawbacks
Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
Upcoming event
POWTECH
23-25 September 2025 | Exhibition | Nuremberg, Germany
See all